The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro
Philip O'Brien(Garvan Institute of Medical Research), R. L. Sutherland(Garvan Institute of Medical Research), Anna DeFazio(The University of Sydney), Neville F. Hacker(New South Wales Department of Health), David I. Quinn(USC Norris Comprehensive Cancer Center), Susan M. Henshall(Garvan Institute of Medical Research), Elizabeth D. Williams(Prostate Cancer Foundation of Australia), Viola Heinzelmann‐Schwarz(Roche (Switzerland)), Jennifer L. Clancy(Corona (Poland)), Caroline Barton(Garvan Institute of Medical Research), Brian Gloss(Garvan Institute of Medical Research), Michael J. Davies(Statens Serum Institut), A N Smith(Garvan Institute of Medical Research), Richard A. Scolyer(The University of Sydney), Darren N. Saunders(Garvan Institute of Medical Research), James Scurry, L Scurr(The University of Sydney), Y Zeng(Monash University), C. K. W. Watts, Kate Patterson(Garvan Institute of Medical Research), Michelle J. Henderson(New South Wales Department of Health)
Cited by 69
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Guidelines and definitions for research on epithelial–mesenchymal transition
|Nature Reviews Molecular Cell Biology|2020|2.3k
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|2.3k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Biochemistry and pathology of radical-mediated protein oxidation
|Biochemical Journal|1997|1.7k